

**President:**

Prof Dr Saqib Siddiq

**Secretary General:**

Dr. Saima Zubair

**Scientific Committee:**

Prof Alison Wright  
Prof Chris Hudson  
Prof M. Tayyab  
Prof Shazia Majid  
Prof M Arshad Chohan  
Prof Shahida Hussain  
Prof Fareed Zafar  
Prof Rizwana Ch.  
Dr Khadija Farhan  
Prof Safia Izhar  
Prof Ghazala Mahmud  
Brig Viqar un Nisa  
Prof Nighat Shah  
Dr Rahat Anwar  
Prof Bushra Rauf  
Prof Rubina Tahir  
Prof Syeda Batool  
Dr Saqib M Ahmed

Memorandum of Understanding (MoU)

Between

**Acumen Pharma (Pvt) Ltd**

and

**Feminine Healthcare Scientific Committee (FHC360)**

Effective Date:

15 July 2024

**President:**

Prof Dr Saqib Siddiq

**Secretary General:**

Dr. Saima Zubair

**Scientific Committee:**

Prof Alison Wright

Prof Chris Hudson

Prof M. Tayyab

Prof Shazia Majid

Prof M Arshad Chohan

Prof Shahida Hussain

Prof Fareed Zafar

Prof Rizwana Ch.

Dr Khadija Farhan

Prof Safia Izhar

Prof Ghazala Mahmud

Brig Viqar un Nisa

Prof Nighat Shah

Dr Rahat Anwar

Prof Bushra Rauf

Prof Rubina Tahir

Prof Syeda Batool

Dr Saqib M Ahmed

**MEMORANDUM OF UNDERSTANDING**

This Memorandum of Understanding (“MoU”) is entered into between:

**1. Acumen Pharma (Pvt) Ltd**

having its principal office at Plot 39 & 40, Street S-2 RCCI Industrial Estate, Rawat, hereinafter referred to as “Acumen Pharma”

AND

**2. Feminine Healthcare Scientific Committee (FHC360)**

having its principal office at 38, Pangea Court, Rainham, London, UK, hereinafter referred to as “FHC360”

Collectively referred to as the “Parties.”

**1. Purpose**

The purpose of this MoU is to establish a collaborative framework between Acumen Pharma and FHC360 for the planning, organization, promotion, and execution of:

- Continuing Medical Education (CME) activities
- Scientific symposia
- National and international conferences
- Workshops and academic forums
- Women’s healthcare awareness and educational programs
- Research-oriented and interdisciplinary scientific events
- 

The collaboration aims to advance professional medical education, scientific exchange, and innovation in women’s healthcare and related medical specialties.

**2. Scope of Collaboration**

The Parties agree to collaborate in the following areas:

**2.1 CME Activities**

- Organizing accredited CME sessions for healthcare professionals
- Facilitating expert lectures, panel discussions, and training workshops
- Supporting medical education initiatives and scientific learning

**2.2 Symposia & Conferences**

- Joint planning and execution of scientific conferences and symposia

## President:

Prof Dr Saqib Siddiq

## Secretary General:

Dr. Saima Zubair

## Scientific Committee:

Prof Alison Wright

Prof Chris Hudson

Prof M. Tayyab

Prof Shazia Majid

Prof M Arshad Chohan

Prof Shahida Hussain

Prof Fareed Zafar

Prof Rizwana Ch.

Dr Khadija Farhan

Prof Safia Izhar

Prof Ghazala Mahmud

Brig Viqar un Nisa

Prof Nighat Shah

Dr Rahat Anwar

Prof Bushra Rauf

Prof Rubina Tahir

Prof Syeda Batool

Dr Saqib M Ahmed

- Promotion of interdisciplinary healthcare discussions
- Engagement of national and international faculty and delegates

### 2.3 Academic & Scientific Support

- Exchange of scientific expertise and educational resources
- Development of conference themes, agendas, and academic content
- Encouraging evidence-based clinical practice and research

### 2.4 Sponsorship & Promotional Activities

- Sponsorship support for educational events where mutually agreed
- Branding and promotional collaboration in compliance with ethical and regulatory standards

### 3. Roles and Responsibilities

Acumen Pharma shall:

- Provide educational sponsorship and logistical support where applicable
- Assist in promotional activities and outreach
- Support event coordination and industry collaboration
- Ensure ethical pharmaceutical practices during all activities

FHC360 shall:

- Lead scientific and academic planning of events
- Coordinate faculty, moderators, and scientific committees
- Manage conference content, accreditation applications, and delegate engagement
- Ensure academic integrity and scientific quality

### 4. Financial Arrangements

Any financial commitments, sponsorship arrangements, revenue-sharing models, or event-specific budgets shall be discussed and agreed upon separately in writing for each activity or event.

### 5. Intellectual Property

Any logos, trademarks, branding materials, scientific content, publications, or educational materials belonging to either Party shall remain the intellectual property of the respective owner unless otherwise agreed in writing.

Neither Party may use the other Party's name or logo without prior written approval.

## President:

Prof Dr Saqib Siddiq

## Secretary General:

Dr. Saima Zubair

## Scientific Committee:

Prof Alison Wright

Prof Chris Hudson

Prof M. Tayyab

Prof Shazia Majid

Prof M Arshad Chohan

Prof Shahida Hussain

Prof Fareed Zafar

Prof Rizwana Ch.

Dr Khadija Farhan

Prof Safia Izhar

Prof Ghazala Mahmud

Brig Viqar un Nisa

Prof Nighat Shah

Dr Rahat Anwar

Prof Bushra Rauf

Prof Rubina Tahir

Prof Syeda Batool

Dr Saqib M Ahmed

## 6. Confidentiality

Both Parties agree to maintain confidentiality regarding proprietary, financial, strategic, or sensitive information exchanged during the collaboration unless disclosure is required by law or mutually agreed upon.

## 7. Duration and Termination

This MoU shall remain effective for a period of ten (10) years from the date of signing unless terminated earlier by either Party through written notice of thirty (30) days.

Either Party may terminate this MoU if the other Party breaches any material provision contained herein.

## 8. Nature of Agreement

This MoU reflects the mutual intentions of the Parties for collaboration and does not create a legally binding partnership, employment relationship, or joint venture unless otherwise specified in separate agreements.

## 9. Dispute Resolution

Any disputes arising under this MoU shall be resolved amicably through mutual discussions between the Parties. If unresolved, the matter shall be subject to the applicable laws and jurisdiction mutually agreed upon by both Parties.

## 10. Signatories

IN WITNESS WHEREOF, the undersigned representatives hereby sign this Memorandum of Understanding on the dates mentioned below.

For Acumen Pharma

For FHC360

Signature: 

Name: Dr Azam Khan

Designation: Chief Executive Officer, Acumen

Date: 15 July 2024

Signature: 

Name: Prof Dr Saqib Siddiq

Designation: President, FHC

Date: 15 July 2024